The Next Covidien Hernia Mesh Bellwether Trial Is Set for 11 January 2027

The next Covidien hernia mesh bellwether trial will begin on 11 January 2027 before Judge Patti B. Saris in the District of Massachusetts, in a case brought by Regina Stephen of Mississippi, who alleges she was implanted with a Symbotex patch during a 2017 ventral hernia repair. The setting lands five months after the first federal Covidien hernia mesh bellwether trial produced an $88 million verdict against Medtronic in Patterson v. Covidien — a number that has been quoted in every consumer-facing write-up since, almost always without the two findings that determine what it is actually worth.

Those findings are that the jury held Covidien liable for a Failure to Warn, and that it found no fraud and awarded no Punitive Damages. An $88 million compensatory award with no punitive component behaves very differently in settlement negotiations from an $88 million award with one, and it is far more vulnerable on post-trial motions. The January date matters because it is the mechanism by which the parties will learn whether Patterson was a data point or an outlier.

When is the next Covidien hernia mesh trial?

The next Covidien hernia mesh bellwether trial is scheduled for 11 January 2027 in the U.S. District Court for the District of Massachusetts, before Judge Patti B. Saris, who has presided over MDL No. 3029 since the Judicial Panel on Multidistrict Litigation (JPML) created it in June 2022. The plaintiff is Regina Stephen, a Mississippi resident who alleges that a Covidien Symbotex composite mesh was implanted during a ventral hernia repair in 2017.

The order was reported by trade services during the week of 15 September 2026. Procedurally it is unremarkable — a pretrial scheduling order fixing deadlines for the parties to propose jury instructions and to file motions in limine about what may and may not be put before the jury. That ordinariness is the point. In a Mass Tort docket that has just absorbed a nine-figure verdict, a routine scheduling order is the court signaling that the Bellwether Trial program continues on its own timetable rather than pausing while the parties digest the result.

Two qualifications belong on the date immediately.

First, Stephen's case has already moved once. It carried a July 2026 setting before being reset, and MDL trial dates are working assumptions rather than commitments. Every experienced practitioner in this docket should treat 11 January 2027 as a planning date, not a fixture.

Second, a scheduled bellwether is the most common casualty of a settlement. If Covidien and the plaintiffs' leadership reach terms before final judgment, the January trial disappears along with the rest of the calendar. That has been the pattern in the neighboring hernia mesh dockets, and it is the outcome the defense has the greatest incentive to pursue after Patterson.

What the first Covidien hernia mesh bellwether trial actually decided

The first federal Covidien hernia mesh bellwether trial opened on 13 July 2026 and ran roughly three weeks. On 4 August 2026 the jury returned $88 million in Patterson v. Covidien, No. 1:22-cv-10153 — $77 million to Larry Patterson and $11 million to his wife Tammy Patterson for loss of consortium. It was the first Covidien hernia mesh case anywhere in the country to reach a verdict.

The underlying allegation is narrow and technical, which is part of why it succeeded. Symbotex is a polyester mesh carrying a resorbable collagen film on the visceral side. The film exists to keep the mesh from adhering to bowel and other organs while tissue integration occurs. Patterson alleged that Covidien represented to implanting surgeons that the collagen barrier would remain effective for roughly thirty days, and that in practice it largely dissolved within about a week. He was implanted in 2017, developed a bowel obstruction in 2020, and underwent a revision operation in which the mesh was removed along with a length of intestine.

The jury accepted that the warnings given to physicians were inadequate. It declined to find fraud. It awarded nothing in Punitive Damages. And it assessed the entire $88 million as compensatory.

Element	Jury finding	Amount
Failure to Warn	For the plaintiff	—
Fraud	Not found	$0
Compensatory damages, Larry Patterson	Awarded	$77,000,000
Loss of consortium, Tammy Patterson	Awarded	$11,000,000
Punitive Damages	Not awarded	$0
Total		$88,000,000

The verdict's architecture: no fraud, no punitive damages

The shape of a verdict tells a defendant more than its size, and the shape here is unusually favorable to Covidien given the headline number.

Start with the doctrine. A warning claim against a medical device manufacturer is filtered through the Learned Intermediary Doctrine: the manufacturer's duty runs to the implanting physician, not to the patient. The question the Patterson jury answered was therefore whether surgeons were told enough about how long the collagen barrier would actually last. That is a documentary question — internal testing, the instructions for use, the sales training materials — and it is the kind of question a plaintiff can win on paper without proving that anyone at the company intended to mislead.

The jury's refusal to find fraud confirms it did exactly that. It concluded the label was inadequate without concluding that Covidien lied. A Design Defect theory, had the verdict rested there instead, would have carried different implications for the rest of the inventory, because a defect finding travels with the product across every claimant while a warnings finding is more easily distinguished case by case on what a particular surgeon knew and when.

The absence of Punitive Damages has three practical consequences.

First, valuation. Punitive awards are the component that turns a bellwether result into a multiplier across an inventory, because they signal jury anger that is not specific to one plaintiff's injuries. A purely compensatory verdict signals only what one badly injured man's damages were worth to one jury in Boston.

Second, appellate exposure. Compensatory awards are reviewed for excessiveness under a standard far more deferential than the constitutional proportionality review that applies to punitive awards, but they are reviewed. A $77 million compensatory award to a single plaintiff invites a remittitur motion on its own terms, and the plaintiff has no punitive cushion to give back.

Third, negotiating posture. Covidien can tell its counterparties, accurately, that a jury which heard three weeks of the plaintiffs' best evidence declined to find that the company acted with the state of mind punitive damages require. That is a materially better story than the one most defendants take out of a first bellwether loss.

None of that makes $88 million a good day for Medtronic. It does mean the verdict is a weaker anchor than its size implies, and it explains why the litigation has not immediately converted into settlement talks.

How many Covidien hernia mesh lawsuits are pending, and where?

MDL No. 3029 held 2,453 pending actions on 1 September 2026, according to the JPML's monthly report of pending dockets. That is the number every competing page quotes, and on its own it understates Medtronic's exposure by roughly a factor of four.

Medtronic's own disclosures describe approximately 7,450 plaintiffs with claims involving the Parietex, ProGrip and Symbotex lines in Massachusetts state court, and roughly 10,350 plaintiffs nationally across all forums. The federal Multidistrict Litigation (MDL) is the smaller half of a two-track litigation, and the state-court consolidation sits in the same commonwealth as the MDL — which means the same juror pool, the same local medical community, and, in practice, the same evidentiary record.

The federal hernia mesh landscape as a whole looked like this on the JPML's 1 September 2026 report:

Federal MDL	Manufacturer	Court	Actions pending, 1 Sep 2026	Status
MDL 2846, Davol/C.R. Bard Polypropylene Hernia Mesh	Becton Dickinson (Bard, Davol)	S.D. Ohio	23,316	Resolution announced 2 Oct 2024; administration continuing
MDL 3029, Covidien Hernia Mesh (No. II)	Medtronic (Covidien)	D. Mass.	2,453	Active bellwether phase; second trial 11 Jan 2027
MDL 2753, Atrium Medical C-Qur	Getinge (Atrium)	D.N.H.	127	Substantially resolved
MDL 2782, Ethicon Physiomesh	Johnson & Johnson (Ethicon)	N.D. Ga.	0	Closed out
Total			25,896

Two features of that table drive strategy. Covidien is now the only hernia mesh MDL with an active trial calendar and no Global Settlement, and it is the only one whose docket is still growing rather than winding down. Where Bard's inventory represents claims being processed toward payment, Covidien's represents claims still being valued.

The product family matters to intake as much as the forum does. MDL 3029 consolidates claims across Parietex, ProGrip and Symbotex, which are materially different constructions — bare and coated polyester meshes, a self-gripping mesh, and a collagen-barrier composite respectively. Product Identification is therefore a live issue in this docket in a way it is not in single-product litigation, and the January bellwether, like Patterson, is a Symbotex case. A defense verdict in January would say something about Symbotex warnings; it would say considerably less about ProGrip.

Is there a Covidien hernia mesh settlement?

No. There is no Covidien hernia mesh settlement, no settlement fund, no Settlement Matrix, and no announced framework. The parties held a series of mediation sessions in late March 2026 and produced no agreement, and nothing has been announced since the Patterson verdict.

The reference point that every claimant's question about settlement is really reaching for is Bard. On 2 October 2024, Becton Dickinson announced an agreement resolving the vast majority of its hernia mesh litigation — the federal MDL in the Southern District of Ohio and the consolidated Rhode Island state proceeding — at an aggregate exceeding $1 billion across more than 38,000 claims, payable over a multi-year period and within the company's existing product litigation reserve.

	Bard / Davol (resolved)	Covidien (unresolved)
Announced	2 October 2024	—
Aggregate	More than $1 billion	—
Claims covered	More than 38,000	—
Implied gross average	Roughly $26,000 per claim before fees, costs and liens	—
Federal actions still pending, 1 Sep 2026	23,316	2,453
Bellwether verdicts before resolution	Mixed, across several trials	One, $88 million for the plaintiff
Trial calendar now	None	11 January 2027

The arithmetic in that table is the most useful discipline available to anyone pricing a Covidien claim today. An aggregate above $1 billion spread across more than 38,000 claims implies a gross average in the mid-five figures before the Contingency Fee, before the Common Benefit Fund holdback, before case costs and before any Medical Lien is satisfied. The figure a claimant nets is a fraction of that. Firm and intake pages circulating projected Covidien averages of $65,000 to $70,000 per claimant are extrapolations from that Bard structure, not court-sourced numbers, and no court has recorded an average Covidien payment because none exists.

Two structural differences argue that Covidien's per-claim economics could land higher than Bard's. The docket is roughly a tenth the size, so severity dilution across a very large inventory is less pronounced; and the one tried case produced a plaintiff verdict rather than a mixed record. Two argue the other way: the absence of Punitive Damages in Patterson, and the fact that a Qualified Settlement Fund (QSF) structure has not even been discussed publicly, which is usually the first visible sign that a global resolution is being built.

What happens to the $88 million verdict now?

The verdict is not final and is not enforceable while post-trial motions are pending. Under the schedule reported in the case, post-trial motions were due on 4 September 2026, and no ruling has been reported as of 24 September 2026. Medtronic has said publicly that it disagrees with the verdict, that it will pursue post-trial relief, and that it will appeal if necessary.

Three distinct steps sit between the jury's number and any payment.

Judgment as a matter of law. Covidien will argue the warnings evidence was legally insufficient — that no reasonable jury could find the instructions for use inadequate, or that the plaintiff failed to prove the inadequacy caused the injury. Warning-causation is the usual pressure point under the Learned Intermediary Doctrine: the defense asks whether the implanting surgeon would have done anything differently had the label said what the plaintiff says it should have said. If the surgeon testified that a different collagen-duration figure would not have changed the choice of mesh, the causal chain breaks regardless of what the label said.

Remittitur. Separately, and more likely to produce movement, Covidien will argue $77 million is excessive for the injury proved and ask the court to reduce it or order a new trial on damages. Remittitur is where large compensatory verdicts in single-plaintiff device cases most often lose value, and the plaintiff has no punitive award to surrender as an alternative.

Appeal to the First Circuit. Whatever survives goes up. An appeal in this posture will take the better part of a year to brief and argue, which places any appellate ruling well past the January 2027 bellwether and probably past a third trial.

Stage	Timing	What it does to the number
Verdict	4 August 2026	$88,000,000
Post-trial motions due	4 September 2026	Filed; no ruling reported
Judgment as a matter of law	Pending before Judge Saris	Could zero the award
Remittitur / new trial on damages	Pending before Judge Saris	Could reduce the award
Second Bellwether Trial, Stephen	11 January 2027	Adds or removes a second data point
First Circuit appeal	Not yet docketed	Affirm, reduce, reverse or remand

The practical implication is that nobody — on either side — currently knows what Patterson is worth. That uncertainty, not the headline, is what the January trial is designed to resolve.

Does the $88 million verdict mean every Covidien case is worth millions?

No. A bellwether verdict prices the case that was tried, not the inventory behind it, and bellwether cases are selected precisely because they are not average.

The selection process cuts both ways but it never produces a representative sample. Leadership on both sides picks cases to test theories: plaintiffs favor strong Specific Causation, clean Product Identification, documented revision surgery and sympathetic facts; defendants favor comorbidities, gaps in the medical record, and Statute of Limitations problems. Patterson involved a 2017 implant, a 2020 bowel obstruction, a revision that removed both mesh and intestine, and a spouse with a viable consortium claim. That is an upper-quartile case in any hernia mesh inventory.

Three filters stand between an $88 million verdict and any individual recovery.

The first is injury severity. Claims involving explant surgery, bowel resection, fistula or chronic infection sit in a different tier from claims of pain without revision. Any Covidien Settlement Matrix, when one exists, will stratify on exactly those facts.

The second is the post-trial and appellate discount already described. A verdict under remittitur motion is not a benchmark; it is a proposal.

The third is the gap between gross and net. From any gross recovery come the Contingency Fee, case costs, the Common Benefit Fund assessment that funds the leadership work every MDL claimant benefits from, and any Medical Lien asserted by Medicare, Medicaid or a private plan. The Bard arithmetic above is the honest reference: a resolution exceeding $1 billion across more than 38,000 claims is a mid-five-figure gross average, and a considerably smaller net one.

The bellwether calendar as a pricing mechanism

An MDL bellwether program exists to generate information both sides can price against. Read as a sequence, the Covidien calendar shows a docket that has produced exactly one data point and is working toward a second.

Date	Event
June 2022	JPML creates MDL No. 3029, In re Covidien Hernia Mesh Products Liability Litigation (No. II), before Judge Patti B. Saris, D. Mass.
Late March 2026	Mediation sessions held; no agreement announced
13 July 2026	First bellwether trial opens, Patterson v. Covidien, No. 1:22-cv-10153
4 August 2026	Jury returns $88 million; failure to warn found, no fraud, no punitive damages
4 September 2026	Post-trial motions due
1 September 2026	JPML reports 2,453 actions pending in MDL 3029
Week of 15 September 2026	Scheduling order sets second bellwether for 11 January 2027 and fixes jury-instruction and motion-in-limine deadlines
11 January 2027	Second Bellwether Trial, Stephen, Symbotex, ventral hernia repair 2017

One verdict cannot support a settlement. Two can begin to, and a defense verdict in January would be worth more to Covidien than the Patterson loss cost it, because it would establish a range rather than a ceiling. That asymmetry is why the defense wants the January trial to happen and why plaintiffs' leadership will weigh whether to press for resolution before it does.

The scheduling order's contents reinforce that reading. Deadlines for proposed jury instructions and motions in limine are the work product of a court preparing to try a case, not one holding a slot open. Judge Saris has run this docket for more than four years and has now seen the evidence once; her rulings on the January motions in limine will be the first indication of whether the Patterson evidentiary record travels.

Why preemption is not the escape hatch it is in drug litigation

Practitioners arriving at this docket from pharmaceutical mass torts tend to ask first about Preemption (Products), because in drug litigation it is the defense that disposes of whole inventories. It does far less work here, and the reason is the regulatory pathway.

Express preemption under the Medical Device Amendments reaches devices that have gone through premarket approval, where the Food and Drug Administration has imposed device-specific requirements that state tort law cannot add to. Surgical meshes of this generation reached the market through the substantially-equivalent clearance route instead, which the Supreme Court has held does not impose the device-specific federal requirements that trigger express preemption. A manufacturer cleared on substantial equivalence to a predicate device is, for these purposes, in much the same position as any other product manufacturer facing state-law Failure to Warn and Design Defect claims.

That has two consequences for the Covidien calendar. The first is that there is no dispositive federal-law motion waiting in the wings to end MDL No. 3029 the way preemption rulings have ended drug dockets — which is why the parties are trying cases rather than briefing a threshold defense. The second is that the fight over what the instructions for use said, and what internal testing showed about the collagen barrier, is the whole case rather than a prelude to it. Patterson was tried on that ground and Stephen will be too.

It also explains why the defense case is built on individual proof rather than global rulings. Where a defendant cannot win the docket at once, it wins claim by claim: surgeon testimony that the label made no difference, comorbidities that supply an alternative explanation for the revision, a gap between implant and symptom that strains Specific Causation, or a filing date that runs into the Statute of Limitations. Those defenses do not scale, but in a docket of this size they do not need to.

What it means for claimants' counsel, defense counsel and funders

For claimants' counsel with Covidien inventory. The valuation exercise has changed but not in the direction the headline suggests. Grade inventory on the two findings that actually moved: warnings adequacy as to the implanting surgeon, and documented revision or explant. Cases without a revision were always the soft tier and the Patterson verdict does nothing for them. Expect leadership to press for a Census Registry or expanded Plaintiff Fact Sheet (PFS) exercise if settlement discussions restart, because no aggregate resolution gets built without one. Treat the Massachusetts state-court track as the larger half of the litigation and staff it accordingly; a Covidien practice run only through the MDL is running on a quarter of the national inventory.

For defense counsel and device manufacturers generally. The verdict is a warnings verdict about a duration representation — how long a resorbable barrier stays intact. That is a claim about a specific quantitative statement in the instructions for use, and it is the kind of claim that can be litigated out of a company's own bench data. The lesson for regulatory and labeling teams is narrower and more actionable than "juries dislike mesh": a numerical performance representation to surgeons invites a comparison against internal testing, and the gap between the two is the case. The absence of a fraud finding is worth preserving as a talking point, but it will not survive a second plaintiff verdict.

For litigation funders and firms holding acquisition costs. Third-Party Litigation Funding priced against Covidien inventory now faces a longer horizon than it did in July. The realistic sequence is post-trial rulings, a January trial that may or may not proceed, and a First Circuit appeal that will not resolve before 2028 unless the parties settle. Underwriting that assumed a global resolution inside twelve months of the first verdict should be revisited; the docket has no Special Master appointed to a settlement process, no QSF, and no announced framework. Cost-of-capital models keyed to a 2027 payout are optimistic on the public record as it stands.

For claimants. The practical reality is that nothing about the January date creates or extends anyone's right to file. Each state's Statute of Limitations runs on its own terms from the injury or its discovery, and a pending MDL does not toll it.

Frequently asked questions

What is Symbotex mesh and why is Covidien being sued over it?

Symbotex is a Covidien composite hernia mesh combining a polyester textile with a resorbable collagen film on the visceral surface, intended to prevent the mesh from adhering to bowel and other organs during tissue integration. Plaintiffs allege that the collagen barrier dissolved in roughly a week rather than the approximately thirty days represented to implanting surgeons, allowing adhesion, obstruction and the need for revision surgery — the theory the Patterson jury accepted as a Failure to Warn on 4 August 2026.

Who is the judge in the Covidien hernia mesh MDL?

Judge Patti B. Saris of the U.S. District Court for the District of Massachusetts has presided over MDL No. 3029, In re Covidien Hernia Mesh Products Liability Litigation (No. II), since the JPML centralized it in Boston in June 2022.

When is the next Covidien hernia mesh bellwether trial?

11 January 2027, in Regina Stephen's case, before Judge Saris in Boston. The date was set by a scheduling order reported the week of 15 September 2026, which also fixed deadlines for proposed jury instructions and motions in limine. Stephen's case was previously set for July 2026 and reset once, so the date should be treated as a planning assumption.

How many Covidien hernia mesh lawsuits are there?

The JPML reported 2,453 actions pending in MDL No. 3029 on 1 September 2026. Medtronic's disclosures describe roughly 7,450 additional plaintiffs in Massachusetts state court and roughly 10,350 nationally across the Parietex, ProGrip and Symbotex lines, so the federal docket represents under a quarter of the total exposure.

Is there a Covidien hernia mesh settlement yet?

No. Mediation sessions in late March 2026 produced no agreement, and no settlement has been announced since the Patterson verdict. The only completed hernia mesh global settlement is Becton Dickinson's Bard and Davol resolution announced on 2 October 2024, which exceeded $1 billion across more than 38,000 claims.

Does the $88 million verdict set the value of other Covidien cases?

No. It prices one selected case that involved a 2017 implant, a 2020 bowel obstruction, revision surgery removing mesh and intestine, and a spousal consortium claim. The award is entirely compensatory, is under post-trial motion including a likely remittitur request, and has not been reduced by fees, costs, the Common Benefit Fund assessment or medical liens.